Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-9 of 9 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-9 of 9 studies
-
Restore CFTR ProteinCompleted with Results
A study to evaluate tezacaftor/ivacaftor in adults with cystic fibrosis and two copies of the F508del mutation , protocol number Vertex VX16-661-114This study evaluated the safety, effectiveness, and tolerability of the drug tezacaftor/ivacaftor (Symdeko®). This study was for people with CF ages 12 and older with two copies of the F508del CFTR mutation who had been taken off lumacaftor/ivacaftor (Orkambi®) due to respiratory side effects.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
25 to 90%
-
Number of Visits:
5
-
Length of Participation:
84 days
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation predicted to have residual function , protocol number Vertex VX-661-108This study evaluated the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) versus ivacaftor alone versus placebo. This study was for people with CF who have one copy of the F508del CFTR mutation and a CFTR mutation associated with residual CFTR function.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
12
-
Length of Participation:
33 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis , protocol number Vertex VX15-661-113This study evaluated the safety and tolerability of the drug tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) in children with CF. This study was for children who have two copies of the F508del mutation or one copy of F508del and a second mutation that is either residual function or results in a gating defect and responds to ivacaftor.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
9
-
Length of Participation:
28 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-661 plus ivacaftor in people with CF who have two copies of the F508del CFTR mutation , protocol number Vertex VX-661-111This study evaluated the safety and effectiveness of the CFTR modulator drug VX-661 in combination with ivacaftor (Symdeko®). This study was for people with CF who have two copies of the F508del CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
60 days
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-107This study looked at the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) compared to placebo. This study was for people with CF who have one copy of the F508del CFTR mutation and a second CFTR mutation that is not likely to respond to this drug therapy.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
20 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation with a gating defect responsive to ivacaftor , protocol number Vertex VX-661-109This study evaluated the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) in people already taking ivacaftor (Kalydeco®).
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
13 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of VX-661 and ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-106This study evaluated the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) compared with placebo. This study was for people with CF who have two copies of the F508del CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
11
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-661 combined with ivacaftor in adults with cystic fibrosis , protocol number Vertex VX-661-103This study evaluated the safety and the best way to dose VX-661 in combination with ivacaftor. This study was for adults with CF who have two copies of the F508del CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Restore CFTR ProteinCompleted with Results
VX-661 alone and in combination with ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-101This study looked at the safety and effectiveness of multiple dose levels of VX-661 alone and in combination with ivacaftor (Kalydeco®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
9
-
Length of Participation:
84 days
-
Showing 1-9 of 9 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More